Tags : Tyvyt

Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study

Shot:     The P-III ORIENT-32 involves assessing of Tyvyt (sintilimab) + Byvasda (bevacizumab, biosimilar) vs sorafenib in a ratio (2:1) for 1L treatment of patients with advanced HCC The study resulted in meeting its 1EPs of PFS and OS, the safety profile is consistent with prior studies, and no new safety signals were identified. Following the […]Read More

Lilly and Innovent Report the Global Expansion of their Alliance

Shots: Innovent to receive $200M up front, $825M as development and commercial milestones along with royalties on net sales of the therapy. Both the companies will retain the right to study Tyvyt in combination with other therapies as part of their own clinical programs Lilly will get an exclusive license for the therapy for geographies […]Read More

Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in

Shots:sstosohShots: The P-II ORIENT-2 study involves assessing TYVYT as monothx. vs paclitaxel/ rinotecan in 190 patients in a ratio (1:1) with advanced or metastatic ESCC who failed 1L treatment The P-II ORIENT-2 resulted in meeting its 1EPs of OS with no news safety signals. The detailed results will be presented at ASCO 2020. The two […]Read More

Innovent and Shenogen Enter into a Collaboration to Evaluate the

Shots: The companies enter into an agreement to evaluate the combination of Innovent’s Tyvyt with Shenogen’s SNG1005 for the patients with advanced cancer  Shenogen has in-licensed SNG1005 and has exclusive rights to develop & commercialize it in Greater China. SNG1005 has completed multiple P-II trials in the US with an approved NMPA’s IND application of […]Read More